Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Report, Transcript and Summary

Good morning, ladies and gentlemen, and welcome to Anika's Third Quarter Earnings Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. This call is being recorded on Friday, November 6, 2026. I will now turn the call over to Matthew Hall, Executive Director of Corporate Development, investor relations. Please proceed.

Good morning. Thank you for joining us for Anika's third quarter 26 earnings call. I am Matthew Hall, Anika's Executive Director of Corporate Development and Investor Relations. Our earnings press release was issued earlier this morning and is available on our Investor Relations website as are our supplementary PowerPoint slides that will be used for discussion today. With me on the call are Steve Griffin, President and Chief Executive Officer and Ian W. McLeod, Senior Vice President, Chief Accounting Officer, and Treasurer. They will present our third quarter 2026 financial results and business highlights. Please take a moment to open the slide presentation and refer to slide 2. Before we begin, please understand that certain statements made during the call today constitute forward looking statements as defined in the Securities Exchange Act of 1.93 thousand. These statements are based on our current beliefs and expectations and are subject to certain risks and uncertainties. The company's actual results could differ materially from any anticipated future results, performance, or achievements. We make no obligation to update these statements should future financial data or events occur that differ from the forward looking statements presented today. Please also see our most recent SEC filings for more information about risks that could affect our performance. In addition, during the call, we may refer to several adjusted or non GAAP financial measures. Which may include adjusted gross margin, adjusted EBITDA, adjusted net income from continuing operations, adjusted earnings per share from continuing operations, which are used in addition to results presented in accordance with GAAP financial measures. We believe that non GAAP measures provide an additional way of viewing aspects of our operations and performance. But when considered with GAAP financial measures and the reconciliation of GAAP measures, they provide an even more complete understanding of our business. A reconciliation of these adjusted non GAAP financial results to the most comparable GAAP measurements are available at the end of the presentation slide deck and our third quarter 2026 press release. With that, I will turn the call over to Steve to discuss the quarter and our progress. Steve?

Good morning, everyone, and thank you for joining us. Our third quarter performance marked another positive in building a stronger, more profitable Anika. Revenue grew 10%, with growth in both our commercial and OEM channels. We improved gross margin year over year expanded adoption of Integrity, completed key manufacturing and pipeline milestones, and strengthened a long-term partnership that will contribute to future growth. These results also reinforce the strategic focus we have built around our core hyaluronic acid platform, and the opportunities it creates across our business. At the start of this year, we established revenue growth as our most important goal for 2026. Through the first 9 months, commercial channel revenue is up 15% and OEM channel revenue is up 11%. That progress reflects the increased focus on our core portfolio, and execution against the 3 priorities we laid out in February. Accelerating sustainable revenue growth, driving operational excellence across the organization, and advancing our hyaluronic acid based innovation pipeline. I will provide updates on each of those priorities including where we are making progress, and where our future work is focused. Our first priority remains accelerating sustainable revenue growth. Commercial channel revenue grew 17% to $14 million dollars in the third quarter. Another record. We continue to see demand across our international OA pain management business and our regenerative portfolio, with CINGAL, MONOVISC, and Integrity contributing to that performance. International OA pain management revenue grew 19% in the quarter supported by sustained demand for CINGAL and MONOVISC. These are established products with an important role in our portfolio. Last quarter, I talked about the benefits of bringing greater focus to the business, and aligning our organization and distributors around our core products. The third quarter results give us further reason to continue that focus. We are investing more in where we see opportunities to grow international sales, including adding new frontline commercial team members in a cost neutral way. Within regenerative solutions, total revenue grew 12%. Integrity revenue grew >30% year over year and increased sequentially bringing year to date growth to 37%. Integrity has generated $7 million in revenue over the trailing 12 months as we enter the fourth quarter, traditionally the strongest seasonal quarter for elective surgery. The larger implant sizes introduced in the fourth quarter of 25 and the first quarter of this year have been an important part of that growth. They have expanded use of Integrity into other tendon including foot and ankle and knee. That matters because the opportunity for the platform extends beyond a single anatomy. Surgeons need the sizes and the instrumentation to use the implant across a broader range of tendon repair procedures. In September, we launched second-generation integrity instrumentation that provides an alternative insertion and deployment option to address differences in surgeon preference. This is a practical enhancement to the platform. Giving surgeons another way to work with the implant as adoption expands. We remain encouraged by Integrity's sequential and year over year revenue growth. Market wide seasonality was more pronounced than usual in the summer months. As has been reported by hospital operators and other orthopedic companies, elective surgical procedures in The US were slower during the third quarter. Our updated commercial channel outlook continues to reflect growth in the fourth quarter, but it is not expected to make up for the softness seen over the summer months. Ian will walk through the updated ranges in his prepared remarks. Turning to the OEM channel, revenue grew 5% in the quarter and 11% through the first 9 months, supported by continued execution with J&J and our non-orthopedic products. Our US orthovisc and monovisc relationships remain an important part of the business, As we discussed last quarter, customer ordering patterns can create variability from 1 quarter to the next, so we look at performance over a longer period, as well as the individual quarter. Last quarter, I also highlighted the opportunity to improve growth and profitability across our broader OEM portfolio. We have several long standing relationships and long standing products, that can contribute meaningfully to revenue and cash flow, This quarter's update includes tangible progress on that work. This month, we entered into a new 10-year distribution agreement with our existing Hyvisc partner, Boehringer Ingelheim, The agreement provides higher transfer pricing, a royalty on end market sales, higher contractual minimum purchases, and upfront and milestone payments. In total, we expect to receive $8 million in payments. With a $4 million upfront payment expected in the first quarter of 2027 and the remaining $4 million tied to commercial volumes. Boehringer has been a trusted partner for more than 20 years and we expect to continue that relationship through the coming decade under our new agreement. Together with our other long term US agreements, these partnerships solidify important revenue streams and illustrate the growing demand for our products. HYALOMATRIX, our HYAFF wound product, is now included within the OEM channel, and we ship the first commercial units to a new OEM distributor during the third quarter. Reintroducing HylaMatrix gives us another way to put our existing technology and manufacturing capabilities to work. Our second priority is strengthening operational discipline and execution. Gross margin was 62% in the third quarter compared with 56% a year ago. That improvement reflects the work underway to make our manufacturing operations more productive, and better able to support demand. We have made progress, but we continue to see opportunities to increase output and improve the way that we run the business. Last quarter, I discussed the capacity expansion on our Monovisc and CINGAL line, and upgrades to our ORTHOVISC and nonorthopedic line. Those projects address constraints in our operation, We have continued that work with stronger production planning, process improvements, and greater sourcing flexibility, Recent progress includes FDA approval of a new aseptic manufacturing process, and validation of a second crosslink filler. These are specific improvements that expand our capacity to meet growing demand. Unit volumes on our crosslink line are now up >50% higher than 2022 levels as we meet demand above our forecasts. We see further opportunity to expand output, As demand continues to grow, we are increasing production and building safety stock to support the business. The objective is to meet customer needs while improving productivity and gross margin over time. Our lean transformation is about improving how we do the work every day, simplifying processes, reducing waste, and addressing constraints where they occur. As I said last quarter, the teams closest to the work have an important role in identifying and solving those problems. This approach remains central to how we improve manufacturing execution, and continue building a more efficient organization. The quarter also illustrates why margin improvement will not necessarily be a straight line. Gross margin was lower than the 65% we reported in the second quarter, primarily because of the mix impact of products. Including the reintroduction of HYALOMATRIX which does not yet include future royalty revenue from product sales, We expect the product's margin contribution to improve as those benefits develop. Turning to our third priority, advancing our HA-based innovation pipeline. Our approach remains focused on applications where our experience with hyaluronic acid and HYAFF can address unmet needs in OA pain management and regenerative solutions. We are investing in the clinical, manufacturing, and quality work needed to move these programs forward. Starting with CINGAL, there are 2 important deliverables to be completed before we file the NDA. The first is the bioequivalence study. We completed enrollment in September, which was earlier than our previously communicated year end target, and are now awaiting completion of the study report. Expected in the first quarter of 27. The second priority is the ongoing CMC work required to support filing as a drug. Based on the progress we have made, we expect to submit the CINGAL NDA before year-end 2027. Turning to HYALOFAST. I want to address The US regulatory status separately from our commercial performance and outlook. In October, we received formal notification from the FDA that our HYALOFAST PMA is not approvable based primarily on the clinical data included in the submission. We continue to believe strongly in HYALOFAST potential in the U.S. market, and are assessing the available regulatory pathways and next steps including discussions with the FDA regarding the additional clinical evidence that may be required to support a future approval. Our revenue guidance continues to exclude U. S. HYALOFAST sales under the approach we adopted last quarter to include only products with regulatory approval or clearance in the relevant market. That keeps our revenue outlook separate from an assumed US outcome. Beyond the later stage programs, we continue to advance preclinical studies of HYAFF fiber for regenerative suture and tape. We remain encouraged by the data we have seen, which we believe will support future approval and launch in a large, established market. This is 1 example of the broader opportunity to apply our biomaterials expertise where it can offer additional regenerative solutions for soft tissue repair. We will continue to share updates on our R&D pipeline as milestones are achieved, and offer further perspective on potential launch timing as visibility improves. With that, I will turn it over to Ian for the financial results and outlook.

Thanks, Steve. Please refer to slide 5 of the presentation. Unless otherwise noted, my comments relate to continuing operations, and comparisons are with the same period last year. I will start with the quarter then discuss our cash position and the updated outlook. During the quarter, total revenue was $30.6 million up 10% from $27.8 million Commercial channel revenue grew 17% to $14 million which represents the highest commercial channel revenue in history. That growth reflects continued demand across international OA pain management, and regenerative solutions. rather than a contribution from a single product or market. International OA pain management revenue grew 19%, led by CINGAL, MONOVISC, and total regenerative solutions revenue grew 12%. Integrity grew >30% year over year and increased sequentially. OEM channel revenue grew 5% to $16.6 million, supported by continued execution with J&J and our non-orthopedic products. We also reintroduced HYALOMATRIX, a HYAFF wound product in the U.S. with first unit shipped to a new OEM distributor partner during the third quarter. We are increasing our full year OEM outlook to reflect the greater contribution from the channel. While continuing to recognize the quarterly variability associated with customer order patterns. Gross margin was 62% compared with 56% last year and 65% in the second quarter. The year-over-year improvement reflects continued progress in manufacturing execution. The sequential decline primarily reflected the mix of products, including HYALOMATRIX. We continue to see opportunities for our productivity gains from stronger planning, process improvements, and higher output. Total operating expenses were $19.5 million, up 4%. Research and development expense was $7.9 million compared with $6.9 million while selling, general, and administrative expense declined to $11.7 million Total G&A, excluding the impact of stock-based compensation, is down 19% compared to the last year. We continue to fund the development and manufacturing work required for our priority programs. While managing the broader expense base. For CINGAL, that includes the bioequivalence study report and CMC activities needed to support the NDA submission. Our GAAP operating loss narrowed to $700 thousand from $3.2 million GAAP loss from continuing operations was $300 thousand or $0.02 per share compared with a loss of $3.2 million or $0.22 per diluted share. Adjusted net income from continuing operations was $3.9 million or $0.29 per diluted share The reconciliations in our earnings materials explain the adjustments from the GAAP results. Adjusted EBITDA was $5.1 million compared with $900 thousand last year. And $7.1 million in the second quarter. The year-over-year improvement reflects the progress in revenue and gross margin and the sequential change is primarily related to the timing of OEM shipments. As discussed on our prior earnings call, our full-year 2026 profitability includes the impact of our investment. in our regenerative solutions business. Previously, we expected a $10 million impact to adjusted EBITDA. We now expect it to be closer to $8 million as a result of disciplined expense management and aligning our talent in the regions driving the highest growth. These incremental benefits are incorporated in our adjusted EBITDA forecast for 2026. We generated $8.4 million of operating cash in the quarter and invested $1.7 million in capital expenditures. We expect to continue investing in CapEx through the fourth quarter and next year. We ended September with $45 million in cash and cash equivalents. Compared with $38.4 million at the end of June. That cash position provides flexibility as we invest in manufacturing and our development priorities. For the first 9 months, operating cash flow was $2.8 million compared with $6.6 million last year. As a result of investments in inventory to support our growing demand increased unit output and capacity expansion. We follow a disciplined capital allocation framework which determines where to invest next. First, we are investing in CapEx to expand our manufacturing capacity to meet increased demand and improve our operational efficiency. Second, we are investing in our regenerative solutions team supporting our recent growth and regular. Regularly evaluate to ensure we are tracking towards returns commensurate with the years of product development in our regenerative portfolio. We also continue to work with J&J on pricing stability in the U.S. OA pain management market. While that stability is achieved, we will provide an update on our capital allocation framework. Turning to our outlook, we are raising the lower end of the full year 2026 total company revenue growth guidance. to 6% to 10%. from 5% to 10% previously. While updating the expected contribution from each channel. We now expect OEM channel revenue growth of 5% to 9% compared with 0% to 5% previously. Commercial channel growth is now expected to be 9% to 13% compared with 12% to 18% previously. The change reflects a greater OEM contribution and updated commercial channel growth including the recent market dynamics related to US elective surgery. We are also raising our adjusted EBITDA margin outlook to 15% to 17% from 13% to 17%. For 2027, we are reaffirming total company revenue growth of flat to 5%. We expect commercial channel revenue growth of 5% to 10% with OEM revenue flat to modestly lower. As we previously shared, our forward guidance does not include any US HYALOFAST sales. With that, I will turn the call back over to Steve.

Thanks, Ian. Through the first 9 months, we have made meaningful progress against our priorities for the year. We delivered double digit revenue growth in both channels, strengthened a long-term partnership, increased manufacturing output, expanded integrity adoption, and completed enrollment in the CINGAL bioequivalence study. Our goal is clear. Translate commercial growth manufacturing efficiency, and better economics into profitability and cash generation. As I have outlined, we will do that by continuing to invest in both our commercial and OEM channels and by advancing our existing and future portfolio. To deliver these improvements, our lean transformation puts the people closest to the work at the center of identifying problems, improving processes, and embracing a culture of continuous improvement. To the many employees listening in on our call today, thank you for your commitment and dedication to our continuous improvement initiatives. I also want to thank our distributor and commercial partners who help bring our products to patients around the world and the patients who place their trust in our therapies. With that, operator, let's now open the line for questions.

Thank you, Steve. Ladies and gentlemen, we will now begin the question-and-answer session. If you would like to ask a question, please press star followed by the number 1 on your telephone keypad. If your question has been answered, you would like to withdraw from the queue, please press star followed by the number 2. And if you are using a speaker phone, please lift your handset before pressing any keys. 1 moment, please. I will compile the roster. First question comes from Michael Petusky with Barrington Research. Please go ahead, Hi.

Hey. Good morning, guys. Lots of really good and interesting disclosure. To discuss. So, Steve, I guess the first question I have in terms of gross margin, it looks like maybe mix could be possibly slightly moving against you, but you continue to sort of work on your manufacturing processes and try and get more efficient. I am just curious as you sort of look out over the next 1, 2, 3 years, do you expect gross margin to sort of stabilize sort of in the low 60s? Do you think there is still some room there? Can you just talk about your longer term outlook? Not looking for like a particular quarter, but just as you sort of think about the puts and takes around gross margin? Thanks.

I appreciate the question, Mike. From a gross margin perspective, I think in the near term, that low 6 sixties makes sense. As I noted in the prepared remarks, the mix does shift a little bit with the reintroduction of some products that as they ramp, they could contribute more profitably. The royalties are received. But think that lower 60s mark is an appropriate 1. As you look out over the longer term, as you noted sort of, let's say, 2 or 3 years, what we are balancing is the desire to want to drive improvement and productivity from a manufacturer perspective, which should improve the gross margin slightly. Up against sort of the pricing dynamic here in the United States OA pain market. And I think as those 2 things play out, you could see them offset each other. At a minimum, what I would like to see try and drive productivity such that we offset any, detrimental pricing impact that is normal in this market. If we are able to really achieve breakthroughs from a manufacturing perspective, you could see gross margin improve. that is not something we have communicated in as a longer term goal quite yet, but internally, those are the types of projects we put in place.

Yeah. So I guess pivoting off of that comment and your earlier comments around pricing stability or lack thereof in OA pain in the U.S. I mean, can you just sort of give any insight sort of on a go-forward, what you guys think you are looking at in 2027 headwinds around OA pricing in The U. S?

Sure. I would say. Let me start with 2026, and then I will move to 2027. So I think 2026 has gone according to plan in terms of the pricing in the OA pain market here in the U.S. We have not really changed our guidance at all. If anything, we have raised our guidance over the course this year on revenue, but that is primarily as a result of increases in volume. I would say price was within our expectations. We do expect to see pricing declines next year, and that is embedded in guidance. You will note that our OEM guidance is flat to modestly lower next year as a result. And I really think that we are working closely with J&J to understand sort of where pricing stability when. Will occur. it is a dynamic market. As you know, in the last 2 years, it is been more dynamic than usual. But it is something we track closely, and I think it is embedded in our guide for next year.

Okay. Yeah.

1 of the things, Mike, too, on 2027. I misspoke on our 2027. I-- it said 5% to 10%. It should be 5% to 15% from the commercial-- on the commercial the commercial, we are adding on the mix. Next year.

Okay. So just for your model. Alright. Alright. Thank you. It aligns with what we had in the earnings release. Okay. Great. Couple more, and then I will let other folks get on here. Steve, I guess, could you talk about the CMC piece of CINGAL? Sounds like that may be a little bit more extensive than I understood. Can you just talk about what needs to be done there and, you know, particularly any of the heavy lifting that needs to be done as you sort of prepare for the NDA by the end of next year.

Sure. So for starters, the CMC work is really to prepare for filing as a drug. And as you know, we manufacture this product that is really monoVisc. That we manufacture that is gonna be filed alongside as part of the CINGAL NDA. But we manufacture today as a medical device, and what we really need to make improvements around is the in process controls associated with, how we manufacture. Which is the expectation for a drug type product. Those initiatives are underway with our teams working internally around what those in process controls may need to look like. And when they are completed, we will be in a position where we are able to file. A couple notes on the Cingal NDA submission. This is the first time we are giving a public sort of comment around when we expect to file, which we said would be before the end of the year next year. And we are pleased to say that we completed the enrollment on the bioequivalent study earlier than initially expected, So earlier in our comments over the course of this year, probably remember that we said that we would expect enrollment to be completed before December of 20 sixth. Right. And that was completed in September. And I kinda noted that we would expect the CMC to kinda lag behind that work. So I expect the clinical study report on bioequivalence to be done in the first quarter, and then we will wrap up our activities to then get to the submission on the NDA.

Okay. Alright. Great. And then, just last 1 for me, and I will I will get back in the queue. Possibly. The 10 year agreement year on Hyvisc, that. that is sort of in. Interesting. And I guess I am just curious. The $4 million upfront payment is that in Q1, is that a part of sort of the flat guidance on OEM for next year? Or is that excluded from that from that guide?

that is implied in the guidance for right now. And if you really think about it, that is gonna be amortized from a GAAP perspective. That will be amortized over 10 years. So it becomes less impactful when you really think about it that way. I wanna just take a moment though and speak about the Hyvisc agreement. So Boehringer has been an excellent partner for us for the last 20 years in distributing 1 of our products in the veterinary space. And we are pleased to be in a position where we are gonna extend that agreement for another 10 years. And more so pleased that around the board, it really is an increase in economics that I think represents the value of our portfolio today, even on our legacy assets and I. The $4 million upfront is important contribution to what we use to make. Continue to make investments in capital expenditures. And on top of that, we will see increases in transfer pricing, royalties, and higher contraction minimums. So, you know, we are excited about that agreement, and we think it is good demonstration of the work that we put into trying to optimize the portfolio that we have in front of us. You know, lastly, Mike, to your comment, you know, when we get further into the beginning of 2027, we will prepare further guidance around what we expect to see throughout the course of the year. Is just our preliminary outlook, it remains the same as to what we shared previously. Okay. Very good. Thank you.

Thank you. Your next question comes from Madison Elsadi with B. Riley. Please go ahead.

Hi. This is Liisa Wang on for Madison. Good morning, and thanks for taking our questions. So I think a lot of good colors from prepared remarks and also the previous Q and A. We just had follow-up on the revenue guidance side. So the implied 4Q seems like a wide range. Maybe more color on what we are looking at. And, also 2027, I know you just mentioned it. But maybe, like, what are the trend or assumptions we are looking at now here? Thank you.

Sure. So let's start with the revenue guidance question as it relates to the fourth quarter We have updated our revenue guidance expectations both on the OEM and on the commercial side. To reflect where we expect to see the fourth quarter play out Overall, the OEM channel is stronger than we initially expected. And the change to the commercial guidance is really just an update associated with integrity we expect to be a little bit lighter than what we had initially expected. When we look at sort of the seasonality, you know, I expect that the fourth quarter. We have had a very strong start to the year. So let me start with that. And I think the timing of our order shipments to our distributors has played a factor in that. Such that the second and the third quarter were quite strong, whereas historically, we have seen the fourth quarter be the strongest quarter for us So when we look at the comps on the fourth quarter, I expect to see more moderated growth, as we look at know, what this fourth quarter will be versus what was a very strong fourth quarter last year. And I would expect to see probably more moderation on the OEM channel and continued growth on the commercial channel. So that is how things play out for us in 26. And then to your question around 2027, what is implied in our guidance, really what is implied there is continued execution, which we have seen now over 7 or 8 years of our international OA pain sales. I noted in our prepared remarks that team continues to execute really well. And we have made investments on our frontline commercial team in a cost neutral way to help accelerate that growth. I think the real element for us is making sure that we can catch up from a manufacturing perspective with the increased demand that they placed on the business. it is a great problem to have, and it is 1 that we are chasing after. that is the foremost element of our, total revenue increases as we think about next year. As well as continued in growth, the. In the integrity business.

Do you have any follow-up? No. that is it. Thank you.

Your follow-up question comes from Michael. Please go ahead.

Okay. Great. Hey. So just a couple more quick ones. On integrity, Steve, in terms of sort of what you are seeing on utilization, reorders and then sort of expanding the doc user footprint. I mean, what can you say your you are happy with, not happy with in terms of the momentum both around sort of utilization reorders and getting new guys familiar with the product. Thanks.

Yeah. it is a good question. I would say across the board, we are pleased with the performance. So, 30% growth year over year, which continuing to grow that business at 37% on a year to date basis. And when we look at surgeons, we are seeing a lot of good reuse in terms of key surgeons that have been, you know, strong in performance and represent, I think, a real demonstration of their belief in the integrity system. In terms of the incremental work that we are doing to try and drive new adoption, I noted in my prepared remarks that we launched a new set of integrity instrumentation, which offers a different set of deployment tools And that is really because I would say surgeons have different deployment preferences. And we wanna be able to meet them with where they are at. So that is the first element around how we are driving incremental surgeon adoption. And then the other element of where we have been able to drive further adoption has been in regards to different shapes and sizes of integrity. So earlier this year and late last year, we launched new shapes and sizes and that expansion has really opened it up to the foot and ankle and knee space. Which is a really good growth market for us. In addition to the shoulder space. So it continues to track really well. I noted in the remarks, though, that there was a little bit of a slower seasonal summertime, which I know some other folks have commented on as well. That certainly had an effect on us because we are not large enough to be able to overcome it. But we have seen a good rebound through the beginning of the fourth quarter.

Okay. Great and then last question. Obviously, a really good quarter in terms of cash generation. I guess as you sort of think about Q4 and then sort of into next year, I mean, obviously, you have a very comfortable balance sheet, you know, no leverage, meaningful amount of cash. But in terms of free cash, I mean, how much of a priority is generating cash relative to maybe different internal investments you guys want to make? And can you just, I guess, any guidance around Q4 because the first 3 quarters have certainly been meaningfully different in terms of free cash generation and then just sort of, I guess, philosophical comments around 2027 and going forward would really be appreciated. Thanks.

Absolutely. Let me start with, expectations for the fourth quarter. I would expect to see positive operating cash flow, and then we expect to make investments from a CapEx perspective. And that is probably also how I would frame the start of, like, what we would expect to see over the course of 27. So, you know, we are very focused on driving the incremental profitability and letting it flow through from an operating cash flow perspective. And we were very intentional about our remarks today that Ian made in regards to our capital allocation framework. Our first use of cash goes into capital expenditures to improve our manufacturing operations. I noted in the comments that we are 50% higher in terms of unit shipments than where we were 4 years ago. That is a great achievement, but at some point, we have to be able to make investments to allow for continued expansion. Of our manufacturing operations as evidenced by the new agreements and the extensions and everything else. We wanna make sure that we are able to get to an appropriate level of manufacturing capacity. So our use of capital will go towards CapEx first. I think as it relates to, you know, longer term guidance in terms of free cash flow conversion or operating cash flow, would not say we are quite there yet in terms of giving a metric, but in terms of philosophically, I look to drive operating cash flow improvement and then stronger, you know, overall capacity expansion through the CapEx investments that we make. It drives quarter-by-quarter variability as you saw first quarter for us always tends to be a little bit higher cash usage and then improvement towards the latter half of the year. And I think that is, to some extent, what we saw throughout the course of this year. So, actually, let me ask a part B to with that question. So in terms, Steve, obviously, of the healthy cash and equivalents you have on the balance sheet. I mean, thoughts on M&A, obviously, the stock has acted terrifically since you gotten the CEO chair, but a possible share repurchase, like how can you just talk about in terms of your balance sheet strength, other than internal investments, I do not suspect you have $45 million of internal investment to make. But can you just talk about how you might consider using some of the balance sheet strength over the next couple of years? Thanks. Yeah. I think it is a it is a appropriate question. And we tried to get ahead of it a little bit in terms of the capital allocation framework. So I will just restate it. So first and foremost is CapEx. The second is the investment we are making in our US sales force, which we are very cognizant of that level of investment we are making. Further down the capital allocation framework, as any company would evaluate, we do evaluate what those options could look like. We have done share repurchases in the past as you have noted. I know. And then I would look at other ways of returning capital to shareholders. that is obviously something we consider. And then M&A is a potential for the business, but I would obviously caution that with the level of improvement that we are looking to drive with our core operations. And where we think we can drive the nearest return on invested capital, I think it is gonna come from internal investment. Just given what we know about our products and our opportunities to improve our margin rates today. that is not to say that over time, those things would be ruled out. Certainly, we remain open to it. And to some extent, it is going to be garnered by sort of the U.S. OA pain market. So that pricing stability is a very important element of our capital allocation framework. And as we get better visibility into that level of stabilization, it will help inform that capital allocation framework. You know? Lastly, Mike, You probably know this, but I have done, you know, a fair amount of M&A in my past, and it can be accretive from a business perspective, and it can create a lot of growth opportunities. But it also has to be balanced against where the business is at. And, obviously, we went through 2 divestitures recently, and really focused our attention on improving operations. I could not be more pleased with the way that our teams have responded through the first 9 months of this year, and I think the performance through the start of the year has been really outstanding, and I think it demonstrates what can happen when we make those types of organic investments. And in the near term, that is where our focus remains. Okay. Very good. Thanks, guys.

Thank you, Mike. Thank you, Michael. There are no further questions at this time. I will turn it back to Steve for some concluding remarks.

Great. Thank you, everybody, for joining our conference call today, we look forward to speaking with you soon.

Ladies and gentlemen, this concludes your conference call for today. We thank you for your participating and ask that you please disconnect your lines. Have a great day.